<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103609</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00027</org_study_id>
    <nct_id>NCT01103609</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients</brief_title>
  <official_title>An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration With AZD1656</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics
      and Pharmacodynamics of Warfarin in T2DM patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).</measure>
    <time_frame>Serial PK blood samples will be taken on days 4-10 during the treatment periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the anticoagulant activity of warfarin upon co-administration with AZD1656 by assessment of prothrombin time (PT) and international normalised ratio (INR).</measure>
    <time_frame>Serial blood samples for warfarin PD measurements will be taken on days 4-10 during the treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of AZD1656 in combination with warfarin by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables (including 7-point glucose), physical examination and adverse events</measure>
    <time_frame>Safety assessments will be monitored throughout the study, from screening visit until follow up visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).</measure>
    <time_frame>Serial PK blood samples will be taken on days 4-10 during the treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily on Day 1 to Day 10, with Warfarin on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice daily on Day 1 to Day 10, with Warfarin on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Oral tablet od on Day 4</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet bd, stepwise increased</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Oral tablet bd, stepwise increased</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of T2DM treated with at least 1000 mg metformin as a single
             treatment or in combination with one other oral anti-diabetics for at least 2 months
             prior to screening. Doses of anti-diabetic treatment stable for at least 1 month

          -  Fasting plasma glucose (FPG) at screening in the range of 6.0 to 15.0 mmol/L (108 to
             270 mg/dL) and FPG in the range of 7.5 to 13.0 mmol/L (135 to 234 mg/dL) on Day 1

          -  Haemoglobin (Hb) A1c &gt;6.5% at screening

        Exclusion Criteria:

          -  Use of drugs with anticoagulant effects 3 weeks prior to first warfarin dosing

          -  Use of amiodarone within 3 months prior to screening and the use of potent CYP450
             inhibitors

          -  Previous treatment with warfarin on clinical indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanko Skrtic</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Ritter, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mirjana Kujacic</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>November 5, 2010</last_update_submitted>
  <last_update_submitted_qc>November 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 2</keyword>
  <keyword>Warfarin</keyword>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

